Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update
Alejandro López-Requenaa, b, Oscar R. Burrone*, b
Identifiers and Pagination:Year: 2009
First Page: 1
Last Page: 8
Publisher Id: TOIJ-2-1
Article History:Received Date: 23/7/2008
Revision Received Date: 8/11/2008
Acceptance Date: 19/12/2008
Electronic publication date: 14/1/2009
Collection year: 2009
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation. One major challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells. We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas. Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed.